Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012

Summary

“Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012” provides data on the Kissei Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Kissei Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Kissei Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Kissei Pharmaceutical Co., Ltd. - Brief Kissei Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Kissei Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Kissei Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Kissei Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Kissei Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Kissei Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Kissei Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Kissei Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Kissei Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Kissei Pharmaceutical Co., Ltd. Snapshot 8
Kissei Pharmaceutical Co., Ltd. Overview 8
Key Information 8
Key Facts 8
Kissei Pharmaceutical Co., Ltd. – Research and Development Overview 9
Key Therapeutic Areas 9
Kissei Pharmaceutical Co., Ltd. – Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products –  Monotherapy 13
Pipeline Products – Combination Treatment Modalities 14
Kissei Pharmaceutical Co., Ltd. – Pipeline Products Glance 15
Kissei Pharmaceutical Co., Ltd. – Late Stage Pipeline 15
Registration Filed Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Kissei Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Kissei Pharmaceutical Co., Ltd. – Early Stage Pipeline Products 19
Pre-Clinical Products/Combination Treatment Modalities 19
Kissei Pharmaceutical Co., Ltd. – Drug Profiles 20
bedoradrine sulfate 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
dexrazoxane 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Glufast + Biguanide 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Glufast + DPP-4 Inhibitor 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
KGA-3235 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
KGO-2142 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
KGO-2173 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
KLH-2109 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
KPS-0373 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
KUX-1151 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
KWA-0711 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ozagrel 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PA-21 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PRX-302 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
remogliflozin etabonate 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
silodosin 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
tranilast 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
YS-110 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Kissei Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration 45
Kissei Pharmaceutical Co., Ltd. – Pipeline Products By Mechanism of Action 46
Kissei Pharmaceutical Co., Ltd. –  Recent Pipeline Updates 48
Kissei Pharmaceutical Co., Ltd. - Dormant Projects 51
Kissei Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
diquafosol tetrasodium 52
KGA-3235 52
remogliflozin etabonate 53
ritobegron 53
VX-745 53
Kissei Pharmaceutical Co., Ltd. – Company Statement 54
Kissei Pharmaceutical Co., Ltd. – Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Kissei Pharmaceutical Co., Ltd., Recent Developments 57
Kissei Pharmaceutical Co., Ltd.- Press Release 57
Sep 25, 2012: Watson Pharma Launches Rapalfo For Treatment Of Benign Prostatic Hyperplasia In Canada 57
Aug 23, 2012: MediciNova Announces Positive Preliminary Results From Phase Ib Study Of COPD Drug MN-221 58
Jul 02, 2012: MediciNova Schedules End-Of-Phase II Meeting With FDA For MN-221 For Treatment Of Acute Exacerbations Of Asthma 59
May 23, 2012: MediciNova Reports Phase IIb Clinical Trial Results Of MN-221 In Asthma Exacerbations 59
Mar 21, 2012: MediciNova Completes Enrollment In Phase II MN-221 Trial Treating Patients Suffering From Acute Exacerbations Of Asthma 61
Dec 09, 2009: New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief 62
Dec 09, 2009: Watson Pharmaceuticals Announces Phase 3 Study Results Of RAPAFLO (Silodosin) For Benign Prostatic Hyperplasia (BPH) 62
Nov 20, 2009: EMEA/CHMP Adopts A Positive Opinion For Silodosin 63
Jul 29, 2009: Recordati Signs Agreement With Nycomed For Co-Marketing Of Silodosin In Italy 63
Jul 20, 2009: MediciNova Evaluates MN-221 For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations 64
Jul 13, 2009: MediciNova Announces Proposed Final Protocol For Its Phase II Placebo-Controlled Clinical Trial Evaluating MN-221 In Patients With Severe Acute Exacerbations Of Asthma 65
May 28, 2009: MediciNova Announces Plan To Modify Its Phase II Placebo-Controlled Clinical Trial Evaluating MN-221 In Patients With Severe Acute Exacerbations Of Asthma 66
May 08, 2009: RAPAFLO (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days 67
Apr 28, 2009: Presented Data Confirm That RAPAFLO (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 68
Apr 22, 2009: MediciNova Reports Final Data from Phase II MN-221 Emergency Department Clinical Trial 68
Apr 07, 2009: Watson Announces United States Availability of RAPAFLO (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH) 70
Jan 12, 2009: MediciNova Reports Interim Phase II Data From MN-221 Emergency Department Study 70
Jan 08, 2009: Application Filed For Dysuria Treatment KMD-3213 In China 72
Financial Deals Landscape 73
Kissei Pharmaceutical Co., Ltd., Deals Summary 73
Kissei Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 75
Partnerships 75
Kissei Pharma Enters Into Research And Development Agreement With Pneuma Partners 75
Kissei Pharma Enters Into Co-Marketing Agreement With USV 76
Licensing Agreements 77
Kissei Pharma Enters Into Licensing, Supply And Collaboration Agreement With Nuon Therapeutics 77
Kissei Pharma Enters Into Licensing Agreement With SpePharm For Dexrazoxane 78
AXIS Enters Into Licensing Agreement With Kissei Pharma For Pilocarpine Hydrochloride 79
Kissei Pharma Enters Into Licensing Agreement With Vifor Pharma 80
Protox Therapeutics Enters Into Licensing Agreement With Kissei Pharma 81
Kissei Pharma Enters Into Licensing Agreement With Eisai For Urief 83
Kissei Pharma Enters Into Licensing Agreement With Y's Therapeutics 84
Kissei Pharma Enters Into Licensing Agreement With GlaxoSmithKline For SGLT-2 85
Kissei Pharma Enters Into Licensing Agreement With Eisai 86
Kissei Pharma Enters Into Licensing Agreement With Eisai For Glufast 87
Kissei Pharma Enters Into Licensing Agreement With GlaxoSmithKline 88
Kissei Pharma Enters Into Licensing Agreement With Elixir Pharma 89
Equity Offering 90
MediciNova Completes Private Placement Of Common Stock And Preferred Stock For $7.5 Million 90
WAKAMOTO Pharma Completes Private Placement With Kissei Pharma 92
JCR Pharma Completes Private Placement With Kissei Pharma 94
Acquisition 96
Kissei Pharma Invests In Hokuyaku 96
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 98
Disclaimer 98

List of Tables
Kissei Pharmaceutical Co., Ltd., Key Information 8
Kissei Pharmaceutical Co., Ltd., Key Facts 8
Kissei Pharmaceutical Co., Ltd. – Pipeline by Indication, 2012 11
Kissei Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2012 12
Kissei Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2012 13
Kissei Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2012 14
Kissei Pharmaceutical Co., Ltd. – Filed, 2012 15
Kissei Pharmaceutical Co., Ltd. – Phase III, 2012 16
Kissei Pharmaceutical Co., Ltd. – Phase II, 2012 17
Kissei Pharmaceutical Co., Ltd. – Phase I, 2012 18
Kissei Pharmaceutical Co., Ltd. – Pre-Clinical, 2012 19
Kissei Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, 2012 45
Kissei Pharmaceutical Co., Ltd. – Pipeline Products By Mechanism of Action, 2012 47
Kissei Pharmaceutical Co., Ltd. – Recent Pipeline Updates, 2012 48
Kissei Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2012 51
Kissei Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2012 52
Kissei Pharmaceutical Co., Ltd., Other Locations 55
Kissei Pharmaceutical Co., Ltd., Subsidiaries 55
Kissei Pharmaceutical Co., Ltd., Deals Summary 73
Kissei Pharma Enters Into Research And Development Agreement With Pneuma Partners 75
Kissei Pharma Enters Into Co-Marketing Agreement With USV 76
Kissei Pharma Enters Into Licensing, Supply And Collaboration Agreement With Nuon Therapeutics 77
Kissei Pharma Enters Into Licensing Agreement With SpePharm For Dexrazoxane 78
AXIS Enters Into Licensing Agreement With Kissei Pharma For Pilocarpine Hydrochloride 79
Kissei Pharma Enters Into Licensing Agreement With Vifor Pharma 80
Protox Therapeutics Enters Into Licensing Agreement With Kissei Pharma 81
Kissei Pharma Enters Into Licensing Agreement With Eisai For Urief 83
Kissei Pharma Enters Into Licensing Agreement With Y's Therapeutics 84
Kissei Pharma Enters Into Licensing Agreement With GlaxoSmithKline For SGLT-2 85
Kissei Pharma Enters Into Licensing Agreement With Eisai 86
Kissei Pharma Enters Into Licensing Agreement With Eisai For Glufast 87
Kissei Pharma Enters Into Licensing Agreement With GlaxoSmithKline 88
Kissei Pharma Enters Into Licensing Agreement With Elixir Pharma 89
MediciNova Completes Private Placement Of Common Stock And Preferred Stock For $7.5 Million 90
WAKAMOTO Pharma Completes Private Placement With Kissei Pharma 92
JCR Pharma Completes Private Placement With Kissei Pharma 94
Kissei Pharma Invests In Hokuyaku 96

List of Figures
Kissei Pharmaceutical Co., Ltd.  – Pipeline by Indication, 2012 10
Kissei Pharmaceutical Co., Ltd.  – Pipeline by Stage of Development, 2012 12
Kissei Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2012 13
Kissei Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2012 14
Kissei Pharmaceutical Co., Ltd.  – Pipeline By Route of Administration, 2012 45
Kissei Pharmaceutical Co., Ltd.  - Pipeline Products By Mechanism of Action, 2012 46